Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Citations
1,260 citations
926 citations
Cites background from "Chemotherapy-induced peripheral neu..."
...Meta-analyses of clinical trials for CIPN prevention report inconclusive results [1,49]....
[...]
594 citations
372 citations
361 citations
References
3,738 citations
"Chemotherapy-induced peripheral neu..." refers background or methods in this paper
...The incidence of neuropathy increased sharply with cumulative dose, with severe neuropathy estimated to occur in 10% of patients after 9 treatment cycles and in 50% after 14 treatment cycles.(138) Neuropathy also increased in incidence and severity with greater single doses....
[...]
...Chronic oxaliplatin-induced sensory neuropathy appears to be dose-dependent, with severe neuropathy typically occurring in 10% to 20% of patients at a cumulative dose of 750 mg/m(2) to 850 mg/m(2) (Table 3).(138) The incidence of neuropathy increased sharply with cumulative dose, with severe neuropathy estimated to occur in 10% of patients after 9 treatment cycles and in 50% after 14 treatment cycles....
[...]
...Initial assessments characterized oxaliplatin-induced neuropathy as largely reversible,(135,138) with a median recovery time of 13 weeks.(138) Studies using clinician-based grading scales identified 0....
[...]
3,252 citations
"Chemotherapy-induced peripheral neu..." refers background in this paper
...Oxaliplatin, a third-generation platinum analog that is active against both early-stage and advanced colorectal cancer, produces significant neurotoxicity, a potential dose-limiting side effect of treatment.(135,136) Oxaliplatin produces 2 spectrums of neurotoxicity: acute, which occurs following infusion, and with chronic administration....
[...]
...7% of patients with severe neurotoxicity at 18 to 48 months after treatment.(135,136)...
[...]
2,321 citations
"Chemotherapy-induced peripheral neu..." refers methods in this paper
...The most common CIPN assessments are clinicianadministered grading scales, including the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Neuropathy Sensory subscale (Table 2).(49) However, there is only a moderate level of interobserver agreement,(50) with 46% to 71% reliability reported between assessors and considerable interscale variation....
[...]
2,030 citations